Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Approves MTPC’s Re-Enrollment 16 Months after Quitting
May 18, 2012
- “Cost-Effective Assessment Inhibits Innovation”: FPMAJ Chairman Naito
May 18, 2012
- Interview with Alfonso G. Zulueta of PhRMA
May 14, 2012
- Greater Concern than Hope about HTA: Mr Zulueta of PhRMA
May 14, 2012
- Participation in TPP to Lead to Higher NHI Prices: JMA VP Nakagawa
May 10, 2012
- 87% of Respondents Affirmative on Introduction of Medicoeconomic Assessment: JAPhMed Survey
May 9, 2012
- JPMA Compiles Manual for Providing Drugs in the Event of Disasters
April 24, 2012
- JPMA Opposes Haste Adoption of Cost-Effective HTA
April 20, 2012
- National Centers for Advanced and Specialized Medical Cares to Join NHO, JLHWO Hospitals in Joint Purchasing
April 20, 2012
- Degree of Drug Contribution Increased Most for HIV and AIDS: JHSF Survey
April 13, 2012
- MREAC Seeks to Contact 70 People Who Passed MR Exam through “Transitional Measure”
April 10, 2012
- CMRs Exceed 3000, Rapidly Increasing in Specialty Care: JCSOA
April 6, 2012
- 4 Specific Measures for Distribution Improvement: JPWA President Bessho
March 29, 2012
- JGA Announces GL for Disclosure of Payments to Medical Institutions by Member Companies
March 29, 2012
- JGA Announces Measures to Ensure Stable Supplies of Generic Drugs
March 27, 2012
- JGA to Start Providing Information in July on Out of Stock Generics
March 27, 2012
- NIBIO Offers Clinical Trial Information on Rare Diseases on Website
March 26, 2012
- Growth of Domestic Pharma Industry Will Require Individualized Strategies: FPMAJ Chairman Shoda
March 23, 2012
- IDMA President Doshi Expresses Hopes for Cooperation with Japanese Pharmaceutical Companies
March 21, 2012
- Drugstore Market Reaches ¥5.8 Trillion, 11 Straight Years of Growth: JACDS Survey
March 19, 2012
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…